Should denosumab (Prolia) be withheld after hip replacement surgery?

Should Denosumab (Prolia) Be Continued or Withheld After Hip Replacement Surgery?

Denosumab should generally be continued after hip replacement surgery in patients with osteoporosis, as it effectively prevents periprosthetic bone loss and there is no evidence requiring routine withholding of this medication in the perioperative period.

Key Evidence and Rationale

The available guidelines do not specifically recommend withholding denosumab after hip replacement surgery. In fact, research evidence demonstrates significant benefits of continuing denosumab in this setting:

Benefits of Continuing Denosumab Post-Hip Replacement

• Denosumab potently prevents early periprosthetic bone loss after uncemented total hip arthroplasty (THA), with BMD in the denosumab group being 32% higher in critical Gruen zones at 12 months compared to placebo 1

• Superior to bisphosphonates for preventing periprosthetic bone resorption: denosumab increased BMD by +11.9% to +8.1% in proximal femoral zones, while risedronate showed losses of -9.6% to -19.2% at 24 months 2

• Reduces osteoclast activity at the bone-prosthesis interface, with 83% fewer osteoclasts compared to placebo in patients undergoing revision surgery 3

Critical Caveat: The Rebound Effect

The most important consideration is NOT to stop denosumab abruptly after hip replacement. If denosumab must be discontinued for any reason:

• Mandatory transition therapy is required: A course of bisphosphonates (typically zoledronic acid) must be administered 6-9 months after the last denosumab dose to prevent rebound bone loss 4, 5

• Rebound risk is severe: Discontinuation without follow-up therapy causes rapid BMD loss and increased risk of multiple vertebral fractures, particularly in patients with prior vertebral fractures 4

• Metabolic rebound occurs: Research shows bone turnover markers exceed baseline levels by 24 months after denosumab discontinuation, with increased dipeptide concentrations indicating active bone resorption 6

Clinical Decision Algorithm

For Patients Currently on Denosumab Undergoing Hip Replacement:

1. Continue denosumab through the perioperative period - maintain the standard 6-month dosing schedule
2. Ensure adequate calcium (1,000-1,200 mg/day) and vitamin D (600-800 IU/day) supplementation 7, 5
3. Monitor for hypocalcemia risk, especially in patients with renal impairment 7
4. Plan long-term continuation given the protective effects on periprosthetic bone

If Denosumab Must Be Stopped:

1. Administer zoledronic acid 6-9 months after the last denosumab dose 4, 5
2. Alternative transition options (if bisphosphonates contraindicated):
   • Teriparatide or other anabolic agents 4
   • SERMs (raloxifene) in postmenopausal women without thromboembolic risk 4
3. Never stop abruptly without transition therapy

Special Populations:

• Severe renal impairment: Denosumab is reasonable but requires careful hypocalcemia monitoring; aminobisphosphonates are not recommended 7, 5
• High fracture risk patients: Continuation is particularly important as these patients benefit most from sustained antiresorptive therapy 8

Perioperative Timing Considerations

The ACR/AAHKS guideline for perioperative management of antirheumatic medications does not specifically address denosumab for osteoporosis in the context of elective joint replacement 9. This absence of specific recommendations to withhold denosumab, combined with the strong evidence for its bone-protective effects around prostheses, supports continuation through surgery.

Common Pitfalls to Avoid

1. Do not confuse denosumab management with bisphosphonate management - they have different pharmacokinetics and stopping protocols
2. Do not stop denosumab "to allow bone healing" - this is counterproductive as it triggers rebound bone loss precisely when periprosthetic bone preservation is critical
3. Do not forget calcium/vitamin D supplementation - mandatory with denosumab to prevent hypocalcemia 7, 5
4. Do not delay restarting if temporarily held - maintain the 6-month dosing schedule to prevent rebound effects

The evidence strongly favors continuing denosumab through hip replacement surgery rather than withholding it, with the critical understanding that if discontinuation becomes necessary, appropriate transition therapy must be implemented to prevent catastrophic rebound bone loss.